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Abstract
There is accumulating evidence that neurotrophins, like brain-derived neurotrophic factor (BDNF), may impact aging
and Alzheimer’s Disease. However, traditional genetic association studies have not found a clear relationship
between BDNF and AD. Our goal was to test whether BDNF single nucleotide polymorphisms (SNPs) impact
Alzheimer’s Disease-related brain imaging and cognitive markers of disease. We completed an imaging genetics
study on 645 Alzheimer’s Disease Neuroimaging Initiative participants (ND=175, MCI=316, AD=154) who had
cognitive, brain imaging, and genetics data at baseline and a subset of those with brain imaging data at two years.
Samples were genotyped using the Illumina Human610-Quad BeadChip. 13 SNPs in BDNF were identified in the
dataset following quality control measures (rs6265(Val66Met), rs12273363, rs11030094, rs925946, rs1050187,
rs2203877, rs11030104, rs11030108, rs10835211, rs7934165, rs908867, rs1491850, rs1157459). We analyzed a
subgroup of 8 SNPs that were in low linkage disequilibrium with each other. Automated brain morphometric
measures were available through ADNI investigators, and we analyzed baseline cognitive scores, hippocampal and
whole brain volumes, and rates of hippocampal and whole brain atrophy and rates of change in the ADAS-Cog over
one and two years. Three out of eight BDNF SNPs analyzed were significantly associated with measures of cognitive
decline (rs1157659, rs11030094, rs11030108). No SNPs were significantly associated with baseline brain volume
measures, however six SNPs were significantly associated with hippocampal and/or whole brain atrophy over two
years (rs908867, rs11030094, rs6265, rs10501087, rs1157659, rs1491850). We also found an interaction between
the BDNF Val66Met SNP and age with whole brain volume. Our imaging-genetics analysis in a large dataset
suggests that while BDNF genetic variation is not specifically associated with a diagnosis of AD, it appears to play a
role in AD-related brain neurodegeneration.
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Introduction
Alzheimer’s Disease (AD) is a neurodegenerative disorder
that results in the increased production of amyloid-B peptide
and Tau protein hyperphosphorylation, as well as the
degeneration and death of neurons. Although the causes of
late-onset AD pathology are unknown, family studies have
demonstrated that complex genetic and environmental
mechanisms contribute to disease risk [1,2]. Since the
elucidation of the APOE locus in 1993 [3], over 660 candidate
genes for AD risk have been identified, however results are
inconsistent between studies [4]. To further characterize
complex genes associated with AD, a growing number of
studies are using an intermediate phenotype approach, which
utilizes biomarkers, such as structural brain imaging of
hippocampal atrophy, as endpoints in genetic analyses of risk.
The brain-derived neurotrophic factor (BDNF) gene has been
a candidate risk gene for diseases involving memory loss due
to its facilitation of long-term plasticity in the hippocampus, a
function that breaks down during the onset of AD. Moreoever,
accumulating evidence points to a protective role for BDNF in
neurons through increased neuroprotection [5,6], and reduction
of Aβ peptide [7]. Post-mortem studies show that BDNF
expression is severely decreased in the hippocampus,
temporal, and frontal cortex in AD [8,9]. Thus, decreased
BDNF in the brain might contribute to advanced aging as well
as AD [10]. There is a well-known functional single nucleotide
polymorphism (SNP) in the 5’ proregion of the human BDNF
gene at nucleotide 196. The SNP results in a Valine (Val) to
Methionine (Met) amino acid substitution at codon 66
(Val66Met, rs6265, G>A). When Val-BDNF and Met-BDNF are
produced together in neuronal cells they form heterodimers,
which alter BDNF trafficking and decrease secretion of BDNF
[11]. Imaging genetics studies, which may be more sensitive
then traditional gene-association studies, have recently
identified a role for the BDNF Val66Met SNP in hippocampal
volume loss [12], memory impairments [13], reduced medial
temporal lobe activity [14] and modified experience-dependent
plasticity in the motor cortex [15] in healthy humans. Increasing
age may also mediate the effects of the Val66Met SNP [16].
Some studies have also shown that variation in this Val66Met
polymorphism may increase risk for Alzheimer’s Disease and
impact cognitive performance [17,18]. However, there is still
conflicting evidence of the relationship between BDNF genetic
variation and AD [19-22], with several studies showing no
relationship. Finally, other functional SNPs in BDNF have been
identified that may impact human brain function [23],
demonstrating the importance of investigating multiple BDNF
SNPs using an AD phenotype approach to clarify BDNF’s role
in brain neurodegeneration.
Thus, our goal was to use neuroimaging and cognitive
phenotypes that have been associated with AD, and test
whether genetic variation in BDNF impacts these phenotypes
in a large sample from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI). ADNI is an NIH-sponsored, multi-site study
assessing MRI, biological, clinical and neuropsychological traits
to measure the progression of mild cognitive impairment (MCI)
and early AD. This large dataset includes approximately 800
participants with imaging data, cognitive, and genetic data at
several time points. There has been one analysis of BDNF
Val66Met and brain metabolism in the ADNI sample [24],
however no studies have investigated the relationship of




Data used in the preparation of this article were obtained
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database (adni.loni.ucla.edu). The ADNI was launched in 2003
by the National Institute on Aging (NIA), the National Institute of
Biomedical Imaging and Bioengineering (NIBIB), the Food and
Drug Administration (FDA), private pharmaceutical companies
and non-profit organizations, as a $60 million, 5-year public-
private partnership. The primary goal of ADNI has been to test
whether serial magnetic resonance imaging (MRI), positron
emission tomography (PET), other biological markers, and
clinical and neuropsychological assessment can be combined
to measure the progression of mild cognitive impairment (MCI)
and early Alzheimer’s disease (AD). Determination of sensitive
and specific markers of very early AD progression is intended
to aid researchers and clinicians to develop new treatments
and monitor their effectiveness, as well as lessen the time and
cost of clinical trials.
The Principal Investigator of this initiative is Michael W.
Weiner, MD, VA Medical Center and University of California –
San Francisco. ADNI is the result of efforts of many co-
investigators from a broad range of academic institutions and
private corporations, and subjects have been recruited from
over 50 sites across the U.S. and Canada. The initial goal of
ADNI was to recruit 800 subjects but ADNI has been followed
by ADNI-GO and ADNI-2. To date these three protocols have
recruited over 1500 adults, ages 55 to 90, to participate in the
research, consisting of cognitively normal older individuals,
people with early or late MCI, and people with early AD. The
follow up duration of each group is specified in the protocols for
ADNI-1, ADNI-2 and ADNI-GO. Subjects originally recruited for
ADNI-1 and ADNI-GO had the option to be followed in ADNI-2.
For up-to-date information, see www.adni-info.org. Data for the
present analysis were downloaded from the ADNI web site
(ADNI-1 data) in November, 2010.
The study reported here involved 745 subjects who had MRI
scans at least at baseline, and some at 24 months, as well as
genetic and cognitive data. Of those subjects, 48 subjects were
excluded for technical reasons, such as major hardware
upgrades during the study (at two sites), miscalibration of
image resolution, excess movement, or failure of one or more
automatic processing methods. Fifty-two subjects were
excluded because they did not meet the genetics quality
BDNF and AD Neurodegeneration
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control (see below for criteria). The final dataset for analysis
included, 175 normal, 316 mild cognitive impairment, and 154
Alzheimer’s disease subjects. The main demographic and
clinical data, including apolipoprotein E4 (ApoE4) carrier data,
are summarized in Table 1.
Ethics Statement
Ethics approval was obtained for each institution involved.
This study was conducted according to Good Clinical Practice
guidelines, the Declaration of Helsinki, US 21CFR Part 50-
Protection of Human Subjects, and Part 56- Institutional
Review Boards, and pursuant to state and federal HIPAA
regulations. Written informed consent for the study was
obtained from all subjects and/or authorized representatives
and study partners before protocol-specific procedures are
carried out. Institutional Review Boards were constituted
according to applicable State and Federal requirements for
each participating location. The protocols were submitted to
Table 1. Baseline Demographic, Clinical, and
Neuroimaging Characteristics of Study Participants.
 Means (SD) where given
 Controls MCI AD
Characteristic n=175 n=316 n=154
Age, y 76.1 (4.9) 75.4 (7.2) 75.4 (7.6)
Male sex, No. (%) 96 (54.8) 204 (64.5) 82 (53.2)
Education level, y 16.2 (2.7) 15.8 (2.9) 14.9 (2.9)
APOE ε4, minor allele No. (%) 55 (31.4) 172 (54.4) 90 (58.4)
GDS score 1.0 (1.2) 1.54 (1.4) 1.6 (1.4)
Clinical Dementia Rating Global Score .00 (.0) .49 (.03) .72 (.23)
MMSE 29.1 (.95) 27.1 (1.8) 23.5 (2.0)
ADAS-COG score 6.05 (2.7) 11.4 (4.4) 18.2 (5.9)
ADAS-COG score 1 year change⌃ -.434 (3.0) 1.04 (4.4) 4.06 (6.4)
ADAS-COG score 2 year change ω -.190 (2.9) 2.94 (5.9) 9.27 (9.1)
Normalized Whole Brain Volume° .685 (.02) .671 (.03) .660 (.03)
Normalized Left Hippocampal Volume° .242 (.03) .212 (.03) .198 (.03)
Normalized Right Hippocampal Volume° .254 (.02) .224 (.03) .210 (.03)
Percent Whole Brain Atrophy (2 years)* -.925 (.95) -1.62 (1.3) -2.71 (1.5)
Percent Left Hippocampal Atrophy (2
years)* -1.82 (1.7) -4.14 (3.3) -6.56 (3.1)
Percent Right Hippocampal Atrophy (2
years)* -1.61 (1.9) -4.23 (3.8) -7.03 (3.9)
MCI, Mild Cognitive Impairment; AD, Alzheimer’s disease; n, number; y, years;
GDS, Geriatric Depression Scale Total score; MMSE, Mini-Mental Status Exam
total score; ADAS-COG, Alzheimer’s disease assessment scale- cognitive
subscale, Total 11; Normalized= normalized to total intracranial volume. For
ADAS-COG change scores, an increased score represents cognitive decline, as
higher scores equal worse performance. ⌃For 1-year change in ADAS-COG Total
11 score, the sample was: ND = 164, MCI = 286, AD = 132. ω For 2-year change
in ADAS-COG Total 11 score, the sample was: ND = 159, MCI = 245, AD = 110. °
For baseline imaging measures, we used a subsample of individuals with baseline
imaging data (Controls = 166, MCI = 281, AD = 131). * For percent atrophy
measures, we used a subsample of individuals that had both baseline and 24
month brain images (Controls = 127, MCI = 179, AD = 75).
doi: 10.1371/journal.pone.0076001.t001
appropriate Boards and their written unconditional approval
obtained and submitted to Regulatory Affairs at the Alzheimer’s
Disease Neuroimaging Initiative Coordinating Center (ADNI-
CC) prior to commencement of the study. Further information
about ADNI can be obtained from www.adni-info.org.
Genetics Data
Samples were genotyped using the Illumina Human610-
Quad BeadChip. All samples and genotypes underwent
stringent quality control (QC). Genotype data were cleaned by
applying minimum call rates (98%) and minimum minor allele
frequencies (0.02). SNPs not in Hardy-Weinberg equilibrium
(P< 1x 10−6) were excluded. We tested for unanticipated
duplicates and cryptic relatedness using pairwise genome-wide
estimates of proportion identity-by-descent. When a pair of
identical samples or a pair of samples with cryptic relatedness
was identified, the sample with a higher number of SNPs that
passed QC were prioritized. Eigenstrat [25] was used to
calculate principal component factors for each sample and
confirm the ethnicity of the samples. Thirteen SNPs in BDNF
passed QC (rs6265(Val66Met), rs12273363, rs11030094,
rs925946, rs1050187, rs2203877, rs11030104, rs11030108,
rs10835211, rs7934165, rs908867, rs1491850, rs1157459).
We used the SNP Annotation and Proxy Search (SNAP) [26] to
determine proxy based linkage disequilibrium using HapMap,
and detailed other information from the selected SNPs from the
International Hapmap Project (http://hapmap.ncbi.nlm.nih.gov/).
We tested for an association of BDNF SNP allele frequency to
Alzheimer’s Disease in the nondemented and AD groups using
Pearson’s [chi]2 test (Table 2). We did not include the MCI
group in this test due to heterogeneity of the sample. We also
list SNP position, location, and type in Table 2. The linkage
disequilibrium (LD) between genotyped variants can be found
in Table S1. For our AD phenotype analysis we analyzed a
subgroup of 8 SNPs, 7 which were independent of each other
(r2 <.4) (rs11030108, rs10501087, rs908867, rs11030094,
rs1491850, rs1157679, rs12273363) as well as rs6265
(Val66Met), which is in LD with rs10501087 (r2 = .817),
however, we wanted to include it for comparability with the
literature.
ADNI Measures
We used hippocampal and whole brain volume (WBV) data
from the Anders Dale Lab (UCSD) available as part of the
ADNI secondary imaging data downloads. Details on their
neuroimaging processing methods are published elsewhere
[27]. For normalization calculations we divided by the UCSD
estimated intracranial volumes. Normalized left hippocampus,
right hippocampus, and whole brain volumes were used as the
baseline brain imaging endophenotypes for genetics analysis.
There were 166 healthy controls, 281 MCI, and 131 AD
individuals with secondary imaging volumes from UCSD that
passed quality controls, were available for download, and had
corresponding genetics data. We calculated a percent change
of normalized left and right hippocampal volume, and WBV,
using normalized baseline and 24 month imaging data. For
percent atrophy measures, we used a subsample of data that
had brain imaging measures at baseline and 2 years that
BDNF and AD Neurodegeneration
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passed UCSD quality controls (Controls = 127, MCI = 179, AD
= 75). As a marker for disease-related cognitive change, we
used the Alzheimer’s Disease Assessment Scale- cognitive
subscale (ADAS-Cog) total score at baseline and calculated 1
and 2-year change scores (subtracting 1 and 2 year scores
from baseline) for longitudinal data. Because both the ADAS-
Cog and the hippocampal and whole brain imaging measures
were not normally distributed across our sample, we log-
transformed all measures and did statistics on these log-
transformed measures.
Neuroimaging Statistics
We completed statistics across all diagnostic groups
(controlling for disease severity, age, sex, and ApoE genotype),
and within diagnostic groups separately (controlling for age,
sex, and ApoE genotype). For tests of association of SNP with
disease phenotype we used univariate statistics within the
general linear model, controlling for multiple test corrections
using Bonferroni correction. In cases where the minor allele
frequency was <.10, heterozygous and minor-allele
homozygous subgroups were grouped together, with means
and statistics representing the joint group. Because BDNF
rs6265 has been shown to have differing effects across age
and between sexes, we also tested for gene-by-age and gene-
by-sex interactions on imaging and cognitive endophenotypes
with this particular SNP, both within and across diagnosis
groups.
Results
None of the tested allele frequencies of the SNPs were
associated with a diagnosis of Alzheimer’s Disease (Table 2).
Overall, three SNPs were significantly associated with the
ADAS-Cog score at baseline or change in ADAS-Cog over
time, which is a measure of disease severity (rs1157659,
Table 2. BDNF SNP Location and Association Details.






MAF Control AD χ2 p value
rs11030094 A/G 27659775 0 Intergenic 0.351 AA: 29.7% (52) AA: 29.2% (45) 1.62 0.805
      AG: 49.1% (86) AG: 48.1% (74)   
      GG: 21.1% (37) GG: 22.7% (35)   
rs925946 G/T 27667202 7427 Intergenic 0.358 GG: 47.4% (83) GG: 46.1% (71) 4.395 0.355
      GT: 45.7% (80) GT: 40.9% (63)   
      TT: 6.9% (12) TT: 13% (20)   
rs10501087 T/C 27670108 2906 Intergenic 0.23 TT: 62.9% (110) TT:69.5% (107) 2.331 0.32
      CC/CT: 37.1% (65) CC/CT: 30.5% (47)   
rs2203877 T/C 27670910 802 Intergenic 0.434 TT: 52.6% (92) TT: 51.3% (79) 0.951 0.622
      CC/CT: 47.4% (83) CC/CT: 48.7% (75)   
rs6265 G/A 27679916 9006 Nonsynonymous 0.175 GG: 66.9% (117) GG: 70.8% (109) 1.313 0.428
      AA/AG: 33.1% (58) AA/AG: 29.2% (45)   
rs11030104 A/G 27684517 4601 Intron 0.2 AA: 63.4% (111) AA: 69.5% (107) 2.563 0.278
      GG/AG: 36.6% (64) GG/AG: 30.5% (47)   
rs11030108 G/A 27695464 10947 Intron 0.367 GG: 47.4% (83) GG: 44.8% (69) 0.751 0.687
      AA/AG: 52.6% (92) AA/AG: 55.2% (85)   
rs10835211 G/A 27701365 5901 Intron 0.3 GG: 57.1% (100) GG: 53.2% (82) 0.535 0.765
      AA/AG: 42.9% (75) AA/AG: 46.8% (72)   
rs7934165 G/A 27731983 30618 Intron 0.425 GG: 25.7% (45) GG:25.3% (39) 1.797 0.773
      AG: 49.1% (86) AG: 46.8% (72)   
      AA: 25.1% (44) AA: 27.9% (43)   
rs1157659 T/C 27741419 9436 Intergenic 0.44 TT: 29.1% (51) TT: 23.4% (36) 0.496 0.341
      CT: 50.3% (88) CT: 54.5% (84)   
      CC: 20.6% (36) CC: 22.1% (34)   
rs12273363 T/C 27744859 3440 Upstream 0.19 TT: 62.3% (109) TT:60.4% (93) 0.405 0.725
      CC/CT: 37.7% (66) CC/CT: 39.6% (61)   
rs908867 C/T 27745764 905 Upstream 0.117 CC: 85.1% (149) CC: 82.5% (127) 0.305 0.512
      TT/CT: 14.9% (26) TT/CT: 17.5% (27)   
rs1491850 T/C 27749725 3961 Intergenic 0.442 TT: 32.0% (56) TT: 34.4% (53) 0.87 0.6
      CT: 47.4% (83) CT: 46.8% (72)   
      CC: 20.6% (36) CC: 18.8% (29)   
MAF- Minor allele frequency. a Chromosome 11 position according to NCBI Build 37.1 genome assembly, b In base pairs. In cases where the minor allele frequency was <.
10, heterozygous and minor-allele homozygous subgroups were grouped together.
doi: 10.1371/journal.pone.0076001.t002
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rs11030094, rs11030108) (Table 3). Of these, rs1157659 was
significantly associated with baseline ADAS-Cog score in the
overall group, as well as the MCI group separately. In regards
to a relationship of BDNF with cognitive decline, there was a
significant association with rs11030094 and change in ADAS-
Cog score in the ND group, and rs11030108 in the MCI group.
There were no significant relationships between BDNF
genotype and cognitive measures in the AD group.
No SNPs were significantly associated with baseline brain
volume measures, however there was a trend for a relationship
between baseline right hippocampal volume and rs11030094 in
the ND group (p = .056). Six SNPs were significantly
associated with hippocampal and/or whole brain atrophy over
two years (rs908867, rs11030094, rs6265, rs10501087,
rs1157659, rs1491850). Only rs11030094 was associated with
percent change in whole brain volume (p = .048), and this was
in the ND group alone. In the combined analysis only rs908867
was associated with an imaging endophenotype, percent of
right hippocampal atrophy over two years (p = .010). ND
subjects had the highest number of associations with imaging
endophenotypes, genetic variation in rs6265 (p = .027) and
rs10501087 (p = .048) (in LD with each other) was associated
with percent of right hippocampal atrophy over two years, and
variation in rs1157659 was associated with left hippocampal
atrophy (p = .025). There were no significant associations
between BDNF genotype and imaging variables in the MCI
group. In the AD group, variation in rs908867 was associated
with percent of right hippocampal atrophy (p = .025), and
variation in rs1491850 was associated with percent left
hippocampal atrophy over 2 years (p = .048). Significant results
are detailed in Table 3.
In our analysis of gene by age interactions with the rs6265
SNP we found a significant interaction (p<.005) with baseline
whole brain volume measure (controlling for sex, diagnostic
classification, and APOE) in the whole dataset, such that
Val/Val homozygotes (n=387) had lower whole brain volume
with increasing age compared to Val/Met (n=174) and Met/Met
individuals (n=17) (Figure 1). We did not find a significant
interaction between rs6265 and age on any of the cognitive
phenotypes. We also did not find a significant interaction
between Val66Met and sex in our sample with any of the
cognitive or imaging phenotypes.
Discussion
Our imaging-genetics analysis in a large dataset suggests
that BDNF genetic variation may play a role in AD-related
cognitive deficits as well as brain neurodegeneration. While we
did not find an association between any of the BDNF SNPs and
AD diagnosis, most likely due to low power, our analysis of
BDNF SNPs in this large dataset confirms and extends a
growing number of studies showing a relationship between
BDNF genetic variation and both memory-related cognitive
performance and brain morphometry in aging individuals,
independent of APOE.
We found that there was a significant relationship between
the BDNF Val66Met (rs6265) SNP and percent of right
hippocampal atrophy over two years in nondemented
Table 3. Significant results from analysis of imaging and
cognitive phenotypes with BDNF SNPs.























rs908867 -3.82(3.8) -4.37 (4.2)  0.01
ND      





















rs6265 -1.38(1.8) -2.05 (2.2)  0.027





rs1157659 -1.33(1.6) -2.25 (1.8)
-1.52
(1.1) 0.025






 1-YearADAS Δ rs11030108
.441
(4.5) 1.65 (4.3)  0.028










rs1491850 -6.66(3.3) -5.96 (2.5)
-8.25
(3.9) 0.048
Table 3 presents significant results from univariate analysis of variance of log-
transformed AD phenotypes and BDNF SNPs, first across all diagnoses groups,
then split into separate analyses. In cases where the minor allele frequency was <.
10, heterozygous and minor-allele homozygous subgroups were grouped together,
with means and statistics representing the joint group. P-values are corrected for
multiple comparisons. HZ = homozygotes, SD= standard deviation, L= Left, R=
Right, Hippo = normalized hippocampal volume, ADAS = ADAS Total 11 Cognitive
Score, 1-Year Δ = 1-Year change score, 2-Year Δ = 2-Year change score, WBV=
normalized whole brain volume, ND = Nondemented, MCI = Mild Cognitive
Impairment, AD = Alzheimer’s Disease. Atrophy measures are annualized percent
change per year. Statistics from All-Diagnoses included age, sex, APOE genotype,
and diagnostic classification as covariates. Statistics from the ND, MCI, and AD
analyses included age, sex, and APOE genotype as covariates.
doi: 10.1371/journal.pone.0076001.t003
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individuals. Moreover we found that individuals who were
heterozygous for the minor-allele of rs10501087, which is in LD
with rs6265, had greater atrophy in the right hippocampal
cortex than those who were homozygous for the major allele.
Val66Met is a common functional polymorphism in the pro-
region of BDNF known to mediate intracellular trafficking of
proBDNF, and the Met-allele has been associated with
disrupted cellular processing and secretion of BDNF [13]. In
mammals, BDNF is highly expressed in the hippocampus [28].
In our analysis of rs6265, the Met-carrier group (minor-allele
carrying group) was associated with higher rates of atrophy in
the hippocampus over time, an AD-related marker of
neurodegeneration. A recent study of glucose metabolism
(FDG-PET) in the ADNI dataset also found that Met carriers
compared with noncarriers had AD-like glucose metabolism in
memory-related regions such as the temporal, parietal,
occipital and hippocampal cortices [24]. Studies have also
shown that the BDNF Val66Met Met-allele carriers have
impaired episodic memory, decreased hippocampal volume, as
well as reduced hippocampal activity during declarative
memory processing [12-14,29,30]. Moreover, a recent study in
the Australian Imaging, Biomarkers and Lifestyle study found
that healthy adults with high Aβ levels who also had a Met
allele of BDNF rs6265 had significant declines in episodic
memory, executive function, and greater hippocampal atrophy
over 3 years [31]. This, along with our data, argues that the
Met-allele may contribute to brain change associated with
preclinical AD in aging individuals. However, a recent study
showed an interaction between BDNF Val66Met and age such
that with increasing age, it was the Val/Val individuals that had
decreased cortical thickness measures, decreased
performance on episodic memory tasks, and reductions in
white matter fractional anisotropy [16]. In addition, one of the
largest studies on this SNP recently reported reductions in
white matter fractional anisotropy (also a marker of
neurodegeneration) in Val/Val homozygotes of the Val66Met
SNP in prefrontal and occipital pathways, as well as
correlations between cognitive performance and loss of white
matter tract integrity [32]. This study was recently corroborated
by a second analysis of diffusion tensor measures in healthy
Figure 1.  Interaction between the BDNF Val66Met (rs6265) variant with age on whole brain volume.  
doi: 10.1371/journal.pone.0076001.g001
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individuals in which they found that the Val allele was
associated with abnormal white matter microstructure [33].
Although our analysis in ND individuals revealed that Met-allele
carriers had significantly increased hippocampal atrophy, we
found a significant interaction between age and baseline whole
brain volume and BDNF rs6265 SNP in our combined
diagnosis group, which showed that Val/Val individuals have
lower whole brain volumes with increasing age compared to
the Met/Met homozygotes and Met-allele carriers. It could also
be that the Met and Val-allele variations function differently in
individuals with ND verses those with AD, as another recent
study on Val66Met in MCI and AD patients found that executive
function was decreased in Val/Val homozygotes with AD
compared to Met carriers [34].
A number of studies have investigated other SNPs in the
BDNF gene and their association with various diseases as well
as phenotypic markers of disease. For instance, a study of
candidate genes for AD in a large French sample found that
rs6265 was not associated with AD risk (nor was rs1157659,
rs11030108, rs908867, rs1491850), however SNP rs11030094
was significantly associated with AD (p=.01, odds ratio .91),
even when adjusted for other AD risk genes such as APOE,
CLU, CR1, and PICALM [35]. In our sample we found that
rs11030094 was associated with cognitive decline over 1 year
in the nondemented group, baseline hippocampal volume (a
trend at p=.056) and whole brain atrophy in the nondemented
group. Similarly, other tagging SNPs implicated in risk for
depression as well as anti-depressant treatment response,
such as rs1491850, rs10501087, rs908867 [36,37], were both
related to increased hippocampal atrophy in our sample of
elderly individuals, highlighting the complexity of this gene and
its involvement in brain disease. Another study found an
association between a SNP in the BDNF gene (C270T), a SNP
that has been associated with late-onset AD in some but not all
studies [19,38-40], and executive function in patients with
Alzheimer’s disease [41]. Circulating serum levels of BDNF
decrease with age, and serum BDNF may mediate age-related
hippocampal decline [42]. Moreover, postmortem research has
shown reductions in hippocampal BDNF levels in elderly
individuals, as well as even lower levels in individuals with AD
[43,44]. While we did not measure either circulating or brain
levels of BDNF, our results build on these previous studies
associating BDNF genotype, which may impact BDNF protein
levels, and hippocampal deterioration. Studies using brain
imaging phenotypes of aging and AD as outcomes for tests of
the role of genetic variation may be more sensitive to the actual
impact of the gene on heterogeneous, complex diseases than
typical diagnostic outcomes, as they are closer to the effect of
the gene.
We tested whether several SNPs were implicated in AD-
related cognitive decline, as measured by change in the ADAS-
Cog test over one and two years; while we did not find a
relationship between the Val66Met SNP and cognitive
outcomes, we found several SNPs associated with this
measure of progression (rs1157659, rs11030094, rs11030108)
independent of ApoE4. Another study also found no
relationship between Val66Met (and C270T and G712-A) and
rates of cognitive decline in AD, however they did not include
our additional SNPs in their analysis [45]. In fact, to our
knowledge, there have been no reports on many of our tested
SNPs, for instance rs1157659, which was associated with both
ADAS scores and hippocampal atrophy in our sample. Thus, it
may be that some SNPs in BDNF, but not others, impact the
clinical course of AD, and those studies testing only a few of
the SNPs in the gene may miss relationships that otherwise are
associated with BDNF.
One limitation to this study could be reduced sensitivity of
our chosen AD phenotypes to actual AD-related
neurodegeneration, as we limited our analyses to test
hippocampal and whole brain volume, and recent studies have
begun using extended brain regions such as the temporal pole,
inferior lateral ventrical, and precuneus as brain imaging
markers of risk. We did not find a relationship between BDNF
SNPs and cognitive measures in the AD group. This could be
because the AD group has less variance on these measures,
or perhaps because BDNF primarily influences aging-related
cognitive decline, as seen in the AD group, but not dramatic
disease-related decline as seen in the AD group. Furthermore,
brain imaging measures of cognitive task related functional
change (functional-MRI) would be more useful in characterizing
the relationship between BDNF and hippocampal functionality
during memory-related tasks. This data may become available
in an ADNI subset for future investigations. In addition, we did
not find a relationship between BDNF SNPs and imaging
phenotypes in the MCI group. The other study using PET
measures to study BDNF in individuals with MCI did find
significant relationships, however they used a voxel-based
approach, which may be useful for future studies interested in
regions other than the medial temporal cortex. Moreover, the
ADNI sample is limited due to a specific age range included in
the study and interactions of age and genetic variation on brain
volume will be more informative when including a larger range
of ages. The ADNI sample is also limited in sample size when
considering longitudinal imaging data of specific genotype and
diagnosis subgroups. While we used Bonferroni-corrected p-
values due to the number of tests across various phenotypes
and genotypes, it will still be important to replicate these
findings in a second data set, and ideally in a larger dataset.
Because of possible functionality of several SNPs identified in
our study and others (ex. rs908867, rs149850, rs10501087), it
will be important to identify the genetic mechanisms of these
SNPs in future studies. Finally, our sample was limited to
Caucasians to avoid genetic stratification across ethnicities,
however BDNF may have differing frequencies and
polymorphisms across ethnicities that would not be
represented in our results. Overall, we found that while BDNF
genetic variation is not specifically associated with AD, it may
play a significant role in aging or AD-related brain
neurodegeneration, specifically in the hippocampus.
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